Pfizer has scored FDA approval for its biosimilar to AbbVie’s megablockbuster Humira, but it can’t launch the product for several years under a patent settlement the companies inked last year. Meanwhile, the company is planning some oncology biosimilar rollouts for
read moreIndustry watchers largely expected that Bristol-Myers Squibb and Celgene would win U.S. antitrust clearance for their $74 billion merger. But what’s perhaps unexpected is that the permission was not unanimous, spelling an ill omen for future large biopharma deals should
read moreRecipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures More: Recipharm bolsters its inhalation and injectables manufacturing with 0M deal for Consort Medical Source: fierce
read moreJohnson & Johnson’s $572 million opioid verdict in Oklahoma made headlines this summer, but the company’s lawyers quickly sought to reduce the figure. Now, the judge has slashed the verdict to $465 million to cover one year of crisis abatement,
read morePHILADELPHIA—With an FDA decision to expand Amarin’s Vascepa label to include cardiovascular risk reduction looming, a new imaging study shows the drug could have an effect on stopping the progression of plaque in the arteries. That could help explain Vascepa’s
read moreThe funding announcement coincides with the launch of Cancer Research UK’s “Right Now” campaign, which aims to show both the realities of the disease and the positive impact research and improved treatments can have on people’s lives. More: £373k awarded
read more© 1994 - 2026 B.M. Pharmaceuticals